Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
Clinical Trials Related to Paclitaxel
Related studies linked through entity extraction aliases.
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
- Status
- UNKNOWN
- Phase
- PHASE3
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
- Status
- UNKNOWN
- Phase
- PHASE2
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
- Status
- COMPLETED
- Phase
- PHASE3
Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)
- Status
- UNKNOWN
- Phase
- PHASE3
De-Escalation Therapy for Human Papillomavirus Negative Disease
- Status
- COMPLETED
- Phase
- PHASE2
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
- Status
- COMPLETED
- Phase
- PHASE2
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Breast Cancer Treatment Based on Organ-like Culture
- Status
- UNKNOWN
- Phase
- N/A